Developing Next-Generation Treatments for Herpes simplex-induced Diseases And for the more details part, you can use: Innovative Molecules GmbH is a drug development company based in Munich, Germany. With the aim to set a new treatment standard for Herpes simplex induced diseases, the company is focused on the development of IM-250, a potent, second generation, clinical stage helicase-primase inhibitor of HSV-1 and HSV-2. Due to its potency, excellent neuronal tissue exposure and long half-life, IM-250 has the potential to disrupt the current treatment of Herpes simplex-induced diseases. With its ambitious clinical program, IM-250 is currently running a phase 1 study while the preparation of a phase 2 trial in herpes genitalis is ongoing. Additional trials such as in HSV encephalitis are being planned.
 

Recent Milestones: Start of Ph1 study for IM-250
Upcoming Milestones: Completion of Ph1 study for IM-250 Products: Antiviral Herpes simplex inhibitor IM-250 I
Investors: EQT Life Science Partners, Jotnur Holding Ltd.
Full Company address & contact details: Lipowskystreet 10, 81373 Munich, Germany, www.innovativemolecules.com